

745  
5000

PCT

INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

International Patent Classification <sup>7</sup> :

C07K 14/705, A01K 67/027

A1

(11) International Publication Number:

WO 00/68268

(43) International Publication Date: 16 November 2000 (16.11.00)

(21) International Application Number: PCT/SE00/00878

(22) International Filing Date: 4 May 2000 (04.05.00)

(30) Priority Data:  
9901659-4 6 May 1999 (06.05.99) SE

(71) Applicant (for all designated States except US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EKSTRAND, Jonas  
[SE/SE]; AstraZeneca R & D Umeå, Tvistevägen 48, S-907  
36 Umeå (SE). EDLUND, Anders [SE/SE]; AstraZeneca  
R & D Umeå, Tvistevägen 48, S-907 36 Umeå (SE).  
JOHANSSON, Thore [SE/SE]; AstraZeneca R & D Umeå,  
Tvistevägen 48, S-907 36 Umeå (SE). LEONARDSSON,  
Göran [SE/SE]; AstraZeneca R & D Mölndal, S-431 83  
Mölndal (SE).

(74) Agent: ASTRAZENECA AB; Global Intellectual Property,  
Patents, S-151 85 Södertälje (SE).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM,  
DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH,  
GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.

(54) Title: HUMAN GABA<sub>B</sub> RECEPTOR 1 PROMOTERS

(57) Abstract

The present invention relates to nucleic acid molecules constituting GABA<sub>B</sub> receptor 1 promoters P1a and/or P1b, and to methods for screening for compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, said methods comprising the use of nucleic acid molecules constituting GABA<sub>B</sub> receptor P1a and/or P1b promoters.